Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US98937L1052
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG01J1MG9D6
ZBIO
Zenas BioPharma, Inc.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
Zenas BioPharma, Inc.
ISIN
US98937L1052
TICKER
ZBIO
MIC
XNAS
REUTERS
ZBIO.OQ
BLOOMBERG
ZBIO US
Fri, 18.09.2026       Zenas BioPharma
US98937L1052

WALTHAM, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that o...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Tue, 08.09.2026       Zenas BioPharma
US98937L1052

WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that i...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Fri, 04.09.2026       Zenas BioPharma
US98937L1052

WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced manage...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Tue, 18.08.2026       Zenas BioPharma
US98937L1052

WALTHAM, Mass., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that on...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Thu, 13.08.2026       Zenas BioPharma
US98937L1052

- Obexelimab BLA submission for the treatment of IgG4-RD accepted by FDA; PDUFA target action date of May 27, 2027 -...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.07.2026       Zenas BioPharma
US98937L1052

WALTHAM, Mass., July 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on July 15, 2026 (t...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Wed, 17.06.2026       Zenas BioPharma
US98937L1052

WALTHAM, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on June 15, 2026 (t...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Thu, 11.06.2026       Zenas BioPharma
US98937L1052

WALTHAM, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced manag...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.06.2026       Zenas BioPharma
US98937L1052

- The INDIGO study met its primary and all key secondary endpoints with statistically significant results -...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.05.2026       Zenas BioPharma
US98937L1052

- BLA submission based on positive results from Phase 3 INDIGO trial -...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 19.05.2026       Zenas BioPharma
US98937L1052

- Safety and efficacy results from the Phase 3 INDIGO trial to be presented by Emanuel Della Torre, M.D., Ph.D., on Thursday June 4, 2026, at 2:45 PM GMT -...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Wed, 13.05.2026       Zenas BioPharma
US98937L1052

– Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on the Phase 3 INDIGO IgG4-RD trial results –...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.04.2026       Zenas BioPharma
US98937L1052

WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on April 15, 2026...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Fri, 27.03.2026       Zenas BioPharma
US98937L1052

WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced the...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.03.2026       Zenas BioPharma
US98937L1052

WALTHAM, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on March 16, 2026...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.03.2026       Zenas BioPharma
US98937L1052

- Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in H2 2026 based on the Phase 3 INDIGO trial results -...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.02.2026       Zenas BioPharma
US98937L1052

WALTHAM, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on February 17, 202...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Tue, 17.02.2026       Zenas BioPharma
US98937L1052

NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Zenas BioPharma, Inc. (NASDAQ: ZBIO) on behalf of the company's shareholders. The investigation seeks to determine whether Zenas BioPharma's directors breached their fiduciary duties in connection with recent corporate actions....
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 09.02.2026       Zenas BioPharma
US98937L1052

- Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks 8 and 12 (p=0.0009) -...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Wed, 04.02.2026       Zenas BioPharma
US98937L1052

WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced management’s presentatio...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 29.01.2026       Zenas BioPharma
US98937L1052

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Thu, 22.01.2026       Zenas BioPharma
US98937L1052

NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Fri, 16.01.2026       Zenas BioPharma
US98937L1052

WALTHAM, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on January 15, 2026 (the “Grant Date”), the Compensatio...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Thu, 15.01.2026       Zenas BioPharma
US98937L1052

NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Fri, 09.01.2026       Zenas BioPharma
US98937L1052

NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Thu, 08.01.2026       Zenas BioPharma
US98937L1052

NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 05.01.2026       Zenas BioPharma
US98937L1052

NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Zenas BioPharma, Inc. (NASDAQ: ZBIO) on behalf of the company's shareholders.  The investigation seeks to determine whether Zenas BioPharma's directors breached their fiduciary duties in connection with recent corporate actions....
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 05.01.2026       Zenas BioPharma
US98937L1052

- Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare -...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Fri, 19.12.2025       Zenas BioPharma
US98937L1052

WALTHAM, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on December 15, 202...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 15.12.2025       Zenas BioPharma
US98937L1052

- Orelabrutinib is the first BTK inhibitor to demonstrate significant clinical activity in a Phase 2 clinical trial for SLE -...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Thu, 20.11.2025       Zenas BioPharma
US98937L1052

NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Zenas BioPharma, Inc. (NASDAQ: ZBIO) on behalf of the company's shareholders. The investigation seeks to determine whether Zenas BioPharma's directors breached their fiduciary duties in connection with recent co...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Wed, 12.11.2025       Zenas BioPharma
US98937L1052

- Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 -...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Tue, 11.11.2025       Zenas BioPharma
US98937L1052

WALTHAM, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced management’s presentatio...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.10.2025       Zenas BioPharma
US98937L1052

- Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 -...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.10.2025       Zenas BioPharma
US98937L1052

- Orelabrutinib, a highly selective CNS-penetrant, oral small molecule Bruton’s Tyrosine Kinase (BTK) inhibitor with best-in-class potential now in Phase 3 development for progressive forms of Multiple Sclerosis (MS) - ...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.09.2025       Zenas BioPharma
US98937L1052

- Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease -...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Tue, 26.08.2025       Zenas BioPharma
US98937L1052

WALTHAM, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for autoimmune diseases, today announced management’s presentations at the following i...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Tue, 12.08.2025       Zenas BioPharma
US98937L1052

- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 -...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.06.2025       Zenas BioPharma
US98937L1052

WALTHAM, Mass., June 20, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on June 16, 2025 (the “Grant Date”), the Compensation C...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Tue, 17.06.2025       Zenas BioPharma
US98937L1052

NEW YORK, June 17, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.06.2025       Zenas BioPharma
US98937L1052

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zenas BioPharma, Inc. (“Zenas” or “the Company”) (NASDAQ: ZBIO) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company’s Offering Documents is...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.06.2025       Zenas BioPharma
US98937L1052

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zenas BioPharma, Inc. (“Zenas” or the “Company”) (NASDAQ: ZBIO) and reminds investors of the June 16, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi &am...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.06.2025       Zenas BioPharma
US98937L1052

LOS ANGELES, June 16, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zenas BioPharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws....
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.06.2025       Zenas BioPharma
US98937L1052

NEW YORK, June 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.06.2025       Zenas BioPharma
US98937L1052

LOS ANGELES, June 16, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Zenas Biopharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws. Shareho...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Sun, 15.06.2025       Zenas BioPharma
US98937L1052

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Zenas To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of Zenas pursuant and/or traceable to Zenas' registration statement for the initial public offering held on or...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Fri, 13.06.2025       Zenas BioPharma
US98937L1052

NEW YORK, June 13, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement a...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Fri, 13.06.2025       Zenas BioPharma
US98937L1052

NEW YORK, June 13, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The law...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.06.2025       Zenas BioPharma
US98937L1052

NEW YORK, June 12, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.06.2025       Zenas BioPharma
US98937L1052

SAN DIEGO, June 12, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma's registration statement issued in connection with Zenas BioPharma's initial public offering (the "IPO") held on or aro...
Read more
Zenas BioPharma
Technical Analysis Termsheets Terminal
Permalink